James B. Jones Sells 850 Shares of Pacira Pharmaceuticals, Inc. (PCRX) Stock

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) SVP James B. Jones sold 850 shares of the business’s stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $41.11, for a total value of $34,943.50. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Pacira Pharmaceuticals, Inc. (NASDAQ PCRX) traded up $1.95 during trading hours on Monday, hitting $42.20. The company had a trading volume of 1,246,428 shares, compared to its average volume of 845,585. The company has a current ratio of 6.99, a quick ratio of 6.24 and a debt-to-equity ratio of 1.03. Pacira Pharmaceuticals, Inc. has a 12 month low of $29.81 and a 12 month high of $58.95.

Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its earnings results on Wednesday, November 8th. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.15. The company had revenue of $67.30 million for the quarter, compared to the consensus estimate of $68.99 million. Pacira Pharmaceuticals had a negative return on equity of 13.77% and a negative net margin of 18.25%. The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period in the previous year, the business earned $0.20 earnings per share. equities research analysts anticipate that Pacira Pharmaceuticals, Inc. will post -0.87 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/11/20/james-b-jones-sells-850-shares-of-pacira-pharmaceuticals-inc-pcrx-stock.html.

A number of hedge funds have recently modified their holdings of the business. Public Employees Retirement System of Ohio raised its position in Pacira Pharmaceuticals by 7.5% during the third quarter. Public Employees Retirement System of Ohio now owns 40,174 shares of the company’s stock valued at $1,509,000 after purchasing an additional 2,808 shares during the period. Granahan Investment Management Inc. MA raised its position in Pacira Pharmaceuticals by 19.6% during the third quarter. Granahan Investment Management Inc. MA now owns 168,464 shares of the company’s stock valued at $6,326,000 after purchasing an additional 27,609 shares during the period. Highbridge Capital Management LLC raised its position in Pacira Pharmaceuticals by 4.4% during the third quarter. Highbridge Capital Management LLC now owns 202,700 shares of the company’s stock valued at $7,611,000 after purchasing an additional 8,618 shares during the period. Cornerstone Capital Management Holdings LLC. purchased a new stake in Pacira Pharmaceuticals during the third quarter valued at approximately $2,267,000. Finally, Oppenheimer Asset Management Inc. raised its position in Pacira Pharmaceuticals by 207.4% during the third quarter. Oppenheimer Asset Management Inc. now owns 7,375 shares of the company’s stock valued at $277,000 after purchasing an additional 4,976 shares during the period. Institutional investors and hedge funds own 99.79% of the company’s stock.

Several analysts have issued reports on the company. Wedbush reissued an “outperform” rating and set a $87.00 price target (up previously from $80.00) on shares of Pacira Pharmaceuticals in a report on Monday. Janney Montgomery Scott set a $27.00 price target on Pacira Pharmaceuticals and gave the company a “sell” rating in a report on Thursday. Canaccord Genuity boosted their price target on Pacira Pharmaceuticals from $33.00 to $38.00 and gave the company a “hold” rating in a report on Thursday, November 9th. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Pacira Pharmaceuticals in a report on Thursday, November 9th. Finally, HC Wainwright restated a “buy” rating and issued a $52.00 price objective on shares of Pacira Pharmaceuticals in a research report on Thursday, November 9th. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the company. Pacira Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $49.71.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Insider Buying and Selling by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply